The last few decadeshave seen a rise in the development and regulations surrounding nonanimal and human-relevant technologies such as microphysiological systems (MPS), computational, and systems approach to drug discovery globally. While there has been an exponential increase in the interest and use of human-relevant methods, particularly MPS models in India, there have also been significant impediments to sustaining this research. Last year, CPHMS had held a round table with MPS technology developers from academia and industry who proposed several suggestions to take this technology from the lab to the market/ end-users.
To take these suggestions further, we recently held a second roundtable meeting, this time with participants from Government bodies (Department of Biotechnology, Ministry of Science and Technology; Indian Council of Medical Research, ICMR), regulatory bodies (Indian Pharmacopoeia Commission, IPC, and Central Drugs Standard Control Organisation, CDSCO), pharma companies (Cadila Healthcare Ltd, Biological E Ltd, Aurigene Discovery Technologies Ltd., Reagene Pvt. Ltd.), and technology developers in academia and industry.
This was a first-of-its-kind multi-stakeholder meeting to enable indigenous development and sustained funding for human-relevant technologies, specifically MPS models in India.
We envision that initiatives towards realizing these recommendations would commence by early next year, leading to achieving the goals raised in the meeting in the near future.